Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Authors:
Open Access
- 4 January 2019
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 36 (2) , 265-277
Abstract
The progressive nature of type 2 diabetes (T2D) means that many patients will require basal insulin therapy at some point in the course of the disease due to β-cell failure. As basal insulin primarily targets fasting plasma glucose, patients may still experience considerable postprandial glucose excursions and therefore require an additional agent to achieve good glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide an alternative to prandial insulin, with the benefits of fewer daily injections, and a lower risk of hypoglycemia and weight gain. Two fixed-ratio combinations (FRCs) of basal insulin and a GLP-1 RA are now available in the USA and the EU: insulin glargine + lixisenatide (iGlarLixi) and insulin degludec + liraglutide (IDegLira). Titratable FRCs are suitable for most patients with T2D and can help to simplify treatment regimens into one daily injection, potentially aiding in patient adherence. The complementary modes of action of the two components target seven of the many known pathophysiologic defects in T2D. FRCs have demonstrated enhanced glycemic control compared with their constituent components alone, comparable risk of hypoglycemia compared with basal insulin alone, and better tolerability compared with the GLP-1RA component alone due to the slower titration. In this article, we discuss the advantages of FRCs over multiple daily injections, present case studies of typical patients who could benefit from FRC therapy, and outline practical considerations for the initiation of FRC therapy in clinical practice. Funding Sanofi.Keywords
Funding Information
- Sanofi
This publication has 59 references indexed in Scilit:
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminDiabetes, Obesity and Metabolism, 2013
- Basal Insulin and Cardiovascular and Other Outcomes in DysglycemiaNew England Journal of Medicine, 2012
- Factors associated with injection omission/non‐adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetes, Obesity and Metabolism, 2012
- Participants’ experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4‐T) trial: qualitative interview studyDiabetic Medicine, 2011
- Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trialDiabetic Medicine, 2010
- How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetesInternational Journal Of Clinical Practice, 2010
- Correlates of Insulin Injection OmissionDiabetes Care, 2010
- Incretin-Based TherapiesDiabetes Care, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008